← Eichor
Study identifier: NCT04467671 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

Condition: HLH - Hypoplastic Left Heart Syndrome · DORV · DILV - Double Inlet Left Ventricle  ·  Sponsor: Nationwide Children's Hospital

PhasePhase 2
Planned participants24
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.

This description comes directly from the study's public registry record.

Talk to the study team

Samantha Fichtner, BSN, RN  ·  614-355-5764  ·  samantha.fichtner@nationwidechildrens.org

Victoria Shay  ·  victoria.shay@nationwidechildrens.org

Always discuss trial participation with your own doctor first.

Locations (1)

Nationwide Children's HospitalColumbus, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04467671